Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase I clinical trial for the treatment of relapsed/refractory non-Hodgkin's lymphoma and B-cell lymphoma. The company also develops MT-4019, a preclinical drug candidate targeting CD38; and other candidates that are in pre-clinical development for the treatment of solid and hematological cancers. It has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma. Molecular Templates, Inc. is headquartered in Austin, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone512-869-1555
Debt
Current Ratio2.80
Quick Ratio2.80
Price-To-Earnings
Sales & Book Value
Annual Sales$3.39 million
Price / Sales48.99
Price / Cash FlowN/A
Price / Book1.57
Profitability
Net Income$-23,140,000.00
Net Margins-118.65%
Return on Assets-10.93%
Miscellaneous
Employees38
OptionableNot Optionable
Molecular Templates (NASDAQ:MTEM) Frequently Asked Questions
What is Molecular Templates' stock symbol?
Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."
When did Molecular Templates' stock split? How did Molecular Templates' stock split work?
Shares of Molecular Templates reverse split on Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, August 1st 2017. An investor that had 100 shares of Molecular Templates stock prior to the reverse split would have 9 shares after the split.
How were Molecular Templates' earnings last quarter?
Molecular Templates Inc (NASDAQ:MTEM) announced its quarterly earnings data on Thursday, November, 15th. The biotechnology company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.15. The biotechnology company had revenue of $6.75 million for the quarter. Molecular Templates had a negative net margin of 118.65% and a negative return on equity of 14.12%. View Molecular Templates' Earnings History.
When is Molecular Templates' next earnings date?
What price target have analysts set for MTEM?
6 equities research analysts have issued 1-year price targets for Molecular Templates' stock. Their predictions range from $15.00 to $18.00. On average, they expect Molecular Templates' share price to reach $15.75 in the next twelve months. This suggests a possible upside of 248.5% from the stock's current price. View Analyst Price Targets for Molecular Templates.
What is the consensus analysts' recommendation for Molecular Templates?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Molecular Templates.
What are Wall Street analysts saying about Molecular Templates stock?
Here are some recent quotes from research analysts about Molecular Templates stock:
- 1. According to Zacks Investment Research, "Molecular Templates Inc. is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies for the treatment of cancers and other serious diseases. Molecular Templates Inc., formerly known as Threshold Pharmaceuticals Inc., is headquartered in Austin, United States. " (1/2/2019)
- 2. LADENBURG THALM/SH SH analysts commented, "Initiating coverage with Outperform rating and $15 PT. We believe Bodies (ETB) platform offers a differentiated MOA based on forced internalization of antibody fragments directly to ribosomes through the Shiga-Like toxin A mechanism of action resulting in disruption of protein synthesis and direct cell-kill. We expect this novel MOA to offer clinical advantages in: 1) monotherapy in refractory setting when receptor expression is maintained despite resistance to prior treatments targeting the receptor (i.e., 2) combination therapy for frontline as a more potent substitute for a antibody therapeutics, and 3) novel targets not amenable to antibodies due to challenges to internalization. We anticipate ETBs will be attractive to pharma and expect partnerships to contribute to 2019-20 news flow." (12/10/2018)
Has Molecular Templates been receiving favorable news coverage?
Media stories about MTEM stock have been trending negative this week, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Molecular Templates earned a media sentiment score of -2.5 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the next few days.
Who are some of Molecular Templates' key competitors?
Some companies that are related to Molecular Templates include CannTrust (CNTTF), Kura Oncology (KURA), Aurinia Pharmaceuticals (AUPH), Eagle Pharmaceuticals (EGRX), ANI Pharmaceuticals (ANIP), Cara Therapeutics (CARA), ChemoCentryx (CCXI), Karyopharm Therapeutics (KPTI), MacroGenics (MGNX), Aptinyx (APTX), ProQR Therapeutics (PRQR), Viking Therapeutics (VKTX), Basilea Pharmaceutica (BPMUF), Omeros (OMER) and CymaBay Therapeutics (CBAY).
Who are Molecular Templates' key executives?
Molecular Templates' management team includes the folowing people:
- Dr. Eric E. Poma Ph.D., CEO, Chief Scientific Officer & Director (Age 47)
- Ms. Jason S Kim, Pres & COO (Age 44)
- Mr. Adam D. Cutler B.A., Chief Financial Officer (Age 45)
- Dr. Barbara A. Ruskin Ph.D., J.D., Sr. VP, Gen. Counsel & Chief Patent Officer
- Mr. Kurt Elster, Exec. VP of Corp. Devel. (Age 52)
How do I buy shares of Molecular Templates?
Shares of MTEM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Molecular Templates' stock price today?
One share of MTEM stock can currently be purchased for approximately $4.52.
How big of a company is Molecular Templates?
Molecular Templates has a market capitalization of $161.64 million and generates $3.39 million in revenue each year. The biotechnology company earns $-23,140,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Molecular Templates employs 38 workers across the globe.
What is Molecular Templates' official website?
How can I contact Molecular Templates?
Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The biotechnology company can be reached via phone at 512-869-1555 or via email at [email protected]
MarketBeat Community Rating for Molecular Templates (NASDAQ MTEM)
MarketBeat's community ratings are surveys of what our community members think about Molecular Templates and other stocks. Vote "Outperform" if you believe MTEM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTEM will underperform the S&P 500 over the long term. You may vote once every thirty days.
